Working Groups

The ADACC Network has thought-provoking working groups that meet virtually.

If you are interested in joining, please email

Adacc_Network@wfusm.edu.

Biomarkers for Risk and Prognosis

Leader:

Jeff Dage, PhD

Indiana University School of Medicine

Michelle Mielke

Wake Forest University School of Medicine

Meets quarterly on the first Wednesday at 10:00 AM ET

As of August 2026, the Effects of Comorbidities on Biomarkers Working Group, led by Dr. Mielke, decided to merge with Dr. Dage's working group due to their shared interest in evaluating the value of Alzheimer's disease and related dementias (ADRD) biomarkers for predicting cognitive impairment and progression to dementia. The merged group recognizes that multiple chronic conditions (MCCs), demographic factors such as race, ethnicity, sex, and age, as well as socioeconomic status, provide predictive value and may also influence or confound the interpretation of biomarkers. However, the group seeks to determine whether the inclusion of ADRD biomarkers can refine or enhance prognostic accuracy and to identify the most appropriate methods for evaluating the impact of MCCs, which are themselves associated with cognitive decline. Through rigorous research and analysis, the working group aims to advance our understanding of dementia risk factors and improve approaches to risk prediction and disease progression assessment.

Ethical Considerations

Leader:

Jalayne Arias, JD, MA

Georgia State University

Meets on the first Wednesday of each month at 2:00 PM ET

Works to ensure accurate, non-deceptive information about ADRD blood-based biomarkers, especially direct-to-consumer tests. This group recently published an opinion paper on real-world patient use of these tests. The group plans further publications and guidelines to promote ethical practices in ADRD biomarker information sharing.

Understudied Populations

Leaders:

Neelum Aggarwal, MD

Rush University Medical Center

Nicole Fowler, PhD, MHSA

Indiana University School of Medicine

Meets on the first Wednesday of each month at 9:00 AM ET

Formed in 2024 to focus on the utility and accessibility of ADRD blood-based biomarkers in understudied populations that reflect real-world patients. Their aim is to utilize datasets to conduct analyses that support other organizations with similar initiatives. Additionally, they offer advice and support to ADACC pilot awardees to help ensure their pilot projects achieve their goals.